COMMUNIQUÉS West-GlobeNewswire

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
27/01/2026
9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations No Bria-IMT™ related [...]
SRx Health Solutions Allocates Further Capital to its Digital Asset Treasury Hedging Strategy, Bringing Total Allocation to $18 Million
27/01/2026
NORTH PALM BEACH, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced allocating further capital to its digital treasury management strategy with the [...]
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
27/01/2026
Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic [...]
Canix Acquires Major Competitor Trym To Create Industry-Leading ERP Management For Cannabis Industry
27/01/2026
Acquisition strengthens cultivation intelligence as Canix positions itself as the premier ERP platform for cannabis operators amid industry consolidation and federal rescheduling SAN FRANCISCO, Jan. 27, 2026 (GLOBE [...]
Evosep Launches IQ/OQ Protocols for the Evosep Eno System at WCBP 2026
27/01/2026
Washington, D.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- WCBP -- Evosep is proud to announce a major advancement in quality assurance for pharmaceutical and regulated laboratories with the introduction of Installation [...]
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
27/01/2026
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced [...]
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
27/01/2026
BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has [...]
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
27/01/2026
VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody [...]
NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark
27/01/2026
Management reiterates strong confidence in NewGen’s long-term fundamentals and disciplined capital allocation strategy BANGKOK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “ [...]
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
27/01/2026
Tablo becomes first dialysis system to clear FDA’s most rigorous cybersecurity standards SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a [...]
Imprivata Pledges Support for CMS “Kill the Clipboard” Initiative to Simplify and Secure Patient Access to Medical Records
27/01/2026
Company commits to advancing interoperability by enabling frictionless, secure access to devices, applications, and medical records for patients and providers WALTHAM, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Imprivata [...]
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
27/01/2026
“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, [...]
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
27/01/2026
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a [...]
Halo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)
27/01/2026
SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The transaction is subject to customary closing conditions and regulatory [...]
Bicycle Health Appoints Rick Dean as Chief Executive Officer to Lead Next Phase of Growth
27/01/2026
Former OncoHealth CEO joins Bicycle Health to continue the company’s momentum ATLANTA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bicycle Health , the nation’s leading technology-enabled virtual medical group delivering scalable [...]
ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial
27/01/2026
Study aims to evaluate promising therapeutics that could slow or halt progression of Parkinson’s disease in prodromal patients ATLANTA and BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a [...]
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
27/01/2026
Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD program HD is a rare, progressive genetic disorder often described as a [...]
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
27/01/2026
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow [...]
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
27/01/2026
Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc [...]

Pages